Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that its FZ-AD005 antibody conjugate for injection for the treatment of advanced solid tumors has successfully completed the first patient enrollment in Phase I clinical trials. The drug is intended for the treatment of advanced solid tumors, including but not limited to small cell lung cancer, large cell neuroendocrine carcinoma, and prostate cancer.

In October 2023, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. received clinical trial application acceptance notice for the drug and obtained clinical trial approval in December 2023. The Phase I clinical study of the drug aims to evaluate its safety, tolerability and pharmacokinetic characteristics in patients with advanced solid tumors, and it is expected to preliminarily evaluate the efficacy of the drug in patients with advanced solid tumors.